Skip to main content

Table 1 Baseline characteristics of 432 patients chronically infected with HCV, treated with peginterferon and ribavirin in Denmark between 1 January 2002 and 1 January 2007

From: Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: A Danish nationwide cohort study

   Whole cohort
   SVR Non-SVR
Total   274 158
Gender Male 177 (64.5) 105 (66.5)
Nationality European 226 (82.5) 146 (92.4)
  Non-European 48 (17.5) 12 (7.6)
Route of infection IDU 145 (52.9) 74 (46.8)
  non-IDU 37 (13.5) 30 (19.0)
  Unknown 92 (33.6) 54 (34.2)
Age at treatment initiation ≤ 45 years 148 (54.0) 49 (31.0)
Genotype 1 59 (21.5) 74 (46.8)
  2 37 (13.5) 13 (8.2)
  3 168 (61.3) 67 (42.4)
  4 6 (2.2) 4 (2.5)
  6 2 (0.7) 0
  Unknown 2 (0.7) 0
HCV-RNA > 600.000 IU/mL 92 (33.6) 77 (48.7)
Elevated ALT 2 × UNL* 149 (54.4) 73 (46.2)
Treating
Department (speciality)
Infectious Diseases 177 (64.6) 101 (63.9)
  Gastroenterology/Hepatology 97 (35.4) 57 (36.1)
Liver biopsy within 3 years Yes 152 (55.5) 98 (62.0)
Treatment completion As planned 193 (70.4) 65 (41.1)
  With dose reduction 55 (20.1) 43 (27.2)
  Ended before scheduled 24 (8.8) 39 (24.7)
  Unknown 2 (0.7) 11 (7.0)
  1. Data according to those achieving sustained virological response (SVR) versus non-SVR.
  2. Numbers in parenthesis is % of persons with SVR and non-SVR respectively.
  3. UNL, upper normal limit
  4. *2 × UNL = ALT > 70 IU/L (female), ALT > 100 IU/L (male)
  5. IDU, Intravenous drug use